AMRX (Amneal Pharmaceuticals) Total Operating Expense: $732 Mil (TTM As of Mar. 2026)


AMRX Amneal Pharmaceuticals Inc AMRX
63 GF Score
Price $17.29
GF Value $7.57
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Amneal Pharmaceuticals Total Operating Expense?

Amneal Pharmaceuticals AMRX +0.12% 63 Total Operating Expense is $732 Mil as of Mar. 2026. GuruFocus rates AMRX with a GF Score™ of 63/100 and a GF Value™ of $7.57 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Amneal Pharmaceuticals's Total Operating Expense for the three months ended in Mar. 2026 was $172 Mil. Amneal Pharmaceuticals's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $732 Mil.

Amneal Pharmaceuticals Total Operating Expense Related Terms

Amneal Pharmaceuticals Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Amneal Pharmaceuticals's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amneal Pharmaceuticals Total Operating Expense Chart

Amneal Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 575.07 595.79 581.82 672.07 715.39

Amneal Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 154.97 174.25 203.49 182.69 171.84
AMRX
63GF Score
Amneal Pharmaceuticals Inc AMRX
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amneal Pharmaceuticals Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $732 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $732 Mil mean?
Amneal Pharmaceuticals (AMRX) has a Total Operating Expense of $732 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Amneal Pharmaceuticals and its competitors.
Is Amneal Pharmaceuticals' Total Operating Expense too high?
Amneal Pharmaceuticals' current Total Operating Expense is $732 Mil. Overall, Amneal Pharmaceuticals has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Amneal Pharmaceuticals' Total Operating Expense compare to INDV and KNSA?
Amneal Pharmaceuticals' Total Operating Expense of $732 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Amneal Pharmaceuticals and its competitors. Amneal Pharmaceuticals's current Total Operating Expense is $732 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amneal Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amneal Pharmaceuticals (AMRX) is currently considered Significantly Overvalued. The stock's GF Value™ is $7.57, compared to a current price of $17.29 — trading 128.4% above its estimated fair value. The current Total Operating Expense is $732 Mil. Amneal Pharmaceuticals' overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Amneal Pharmaceuticals (AMRX), the current Total Operating Expense is $732 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amneal Pharmaceuticals (AMRX) Overvalued in 2026?

Based on GuruFocus' analysis, Amneal Pharmaceuticals stock appears to be overvalued. The current stock price of $17.29 is trading 128.4% above its estimated GF Value™ of $7.57. GuruFocus considers Amneal Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for AMRX:

  • Total Operating Expense: $732 Mil
  • GF Value™: $7.57 vs. price of $17.29 (128.4% above fair value)
  • GF Score™: 63/100 with 6 warning signs

No single metric tells the full story. See the AMRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amneal Pharmaceuticals Business Description

Other Exchanges 2DT:Germany
Address 400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ, USA, 08807
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
63GF Score

Get the complete analysis for AMRX

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.29
Price
$7.57
GF Value